stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) Return on equity
QIAGEN N.V.'s return on equity over the twelve months to 30 June 2026 was 11.9%, up 0.4 percentage points from fiscal 2025 (11.6%). Over the past ten years it has ranged from −1.60% (fiscal 2019) to 17.4% (fiscal 2021); the current reading is higher than 73% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 11.6% | 9.30 |
| FY2024 | 2.27% | (7.11) |
| FY2023 | 9.38% | (3.52) |
| FY2022 | 12.9% | (4.49) |
| FY2021 | 17.4% | 3.92 |
| FY2020 | 13.5% | 15.07 |
| FY2019 | −1.60% | (8.96) |
| FY2018 | 7.36% | 5.79 |
| FY2017 | 1.57% | (1.54) |
| FY2016 | 3.11% | (1.87) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 153.9% |
| MEDP Medpace Holdings, Inc. compare | 117.9% |
| QGEN QIAGEN N.V. | 11.9% |
| ICLR ICON PLC compare | 4.86% |
| CRL Charles River Laboratories International, Inc. compare | 1.21% |
| BLLN BillionToOne, Inc. compare | 0.00% |
| RVTY Revvity Inc. compare | 0.00% |
| RDNT RadNet, Inc. compare | −1.64% |
| GRAL GRAIL, Inc. compare | −17.3% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement